The study of selective COX-2 inhibitor in the treatment of chronic pelvic pain syndrome

Hang Yin,Xiaofeng Wang,Wenjun Bai,Yongping Zhao,Bo Yang
DOI: https://doi.org/10.3969/j.issn.1008-0848.2008.07.005
2008-01-01
Abstract:Objective: To investigate the mechanism of Type IIIB CPPS and determine reasonable clinical guidance for treatment of it by comparing the efficacy of COX-2 inhibitor and other drugs. Methods: The total of 87 patients with CPPS were first screened by physical examination, urine and EPS analysis and NIH-CPSI score, and then they were divided randomly into three groups including 27 cases treated with Terazosin (Group I), 29 cases treated with Celecoxib (Group II), and 31 cases treated with Celecoxib and Terazosin(Group III). All patients received drug therapy for 4 weeks. Symptom scores (NIH-CPSI) and urodynamic indexes were evaluated and the expression of COX-2 and PGE 2 in EPS of CPPS patients and normal asymptomatic controls were respectively detected by Western Blot and Enzyme-Linked Immumosorbent Assay pre- and post-treatment. Results: (1)Before treatment, the levels of COX-2 and PGE2 in EPS were significantly higher in treated group than those in normal controls (P<0.05), but no statistical significance was found between each treated group(P>0.05). (2) After treatment, the levels of COX-2 and PGE2 in EPS of treated group were significantly lower than those in EPS of pre-treatment counterparts (P<0.05) but no statistical significance was found between each group (P>0.05). (3)There was a significant difference in NIH-CPSI score of treated group between pre- and post treatment (P<0.05) whereas no significant difference was found between each group. Conclusion: The levels of COX-2 and PGE2 in EPS might play an important role in CPPS and were associated with symptoms of CPPS. All of Selective COX-2 inhibitor and Alpha 1-adrenoceptor antagonist reduced the levels of inflammation factors in EPS. The combination of selective COX-2 inhibitor with alpha 1-adrenoceptor antagonist might improve clinical efficacy for CPPS treatment.
What problem does this paper attempt to address?